Adding SBRT to systemic therapy could boost outcomes for some locally advanced hepatocellular carcinoma patients
Recent results from the Phase III NRG-RTOG 1112 clinical study showed that the addition of stereotactic body radiotherapy (SBRT) to systemic therapy with sorafenib significantly improved progression-free survival (PFS) and ...
Dec 19, 2024
0
20









